TITLE

DIATOS AND MEDAREX SIGN CANCER PRODUCT LICENSING AGREEMENT

PUB. DATE
June 2003
SOURCE
Worldwide Biotech;Jun2003, Vol. 15 Issue 6, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the cancer product licensing agreement signed by Diatos SA and Medarex Inc. in June 2003.
ACCESSION #
9902681

 

Related Articles

  • Drug delivery agreement.  // Pharmaceutical Technology Europe;Sep2002, Vol. 14 Issue 9, p16 

    Reports the partnership between OctoPlus Technologies and Diatos SA. Impact of the partnership on the drug delivery of the companies; Grants received by the partners from the French and Dutch governments; Strengths of the partnership.

  • ASCO ROUNDUP.  // BioWorld International;6/6/2007, Vol. 12 Issue 23, p9 

    This section presents the results of data released at the American Society of Clinical Oncology annual meeting in Chicago, Illinois. Data from a Phase I/IIa trial of Quinamed in heavily pretreated patients with solid tumors is presented by ChemGenex Pharmaceuticals Ltd. Data of Phase I study of...

  • MEDAREX/NEURO THERAPEUTICS TO DEVELOP ANTIBODY THERAPEUTICS.  // Worldwide Biotech;Jun2001, Vol. 13 Issue 6, p8 

    Announces the collaboration of Medarex Inc. with Nuero Therapeutics Inc. to develop a full human antibody therapeutics for central nervous system.

  • Medarex arms the immune system. Rodetis, Susan // Equities;Apr95, Vol. 43 Issue 4, p14 

    Focuses on the company Medarex which was established as a joint venture between Dartmouth Medical School and Essex Chemical. Research on how to combat cancer; Effectiveness of Medarex's product MDX-210 in targeting tumor cells; Partnership with E. Merck; Alliance with French cellular therapy...

  • Medarex Moving Forward With Antibody Developments.  // Chemical Market Reporter;5/28/2001, Vol. 259 Issue 22, p8 

    Focuses on an antibody development center and manufacturing facility opened by Medarex Inc. in Greenwich Township, New Jersey. Capacity of the manufacturing facility; Background of Medarex; Purpose of Medarex in establishing the facility.

  • Distinguished service. Horton, Kathleen // Pharmaceutical Executive;Jul97, Vol. 17 Issue 7, p90 

    Announces the appointment of Irwin Lerner as chairman of biopharmaceutical company Medarex.

  • MEDAREX/ZYMOGENETICS TO DEVELOP ANTIBODY THERAPEUTICS.  // Worldwide Biotech;Dec2000, Vol. 12 Issue 12, p2 

    Deals with the alliance between Medarex Inc. and ZymoGenetics Inc. which aims to develop fully human antibody therapeutics. Reports that Medarex, Inc. and ZymoGenetics, Inc. have formed an alliance to develop fully human antibody therapeutics. Plans of the companies to combine Medarex's fully...

  • MEDAREX/ZYCOS SIGN PACT TO DEVELOP ANTIBODY THERAPEUTICS.  // Biotech Business;Mar2002, Vol. 15 Issue 3, p1 

    States that Medarex Inc. and ZYCOS Inc. have signed a collaboration agreement to co-develop novel antibody therapeutic products.

  • More improvements.  // Pharmaceutical Executive;Jul98, Vol. 18 Issue 7, p92 

    Focuses on the intermediate results of Phase II clinical trials involving MDX-210, an antibody, as announced by Medarex. Findings of the research on cancer patients who had failed all standard treatments; Information on MDX-210 and HER-2.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics